LLIVE: A non-interventional multicenter study of first-line Avastin® (bevacizumab) in combination with chemotherapy in patients with metastatic colorectal cancer in Lebanon

被引：0
|
作者：
Ali, Shamseddine [1 ]
Sarah, Abdel Massih [1 ]
George, Chahine [2 ]
Fadi, Nasr [3 ]
Joseph, Kattan [4 ]
Fadi, Farhat [5 ]
Bassim, Kobrossy [6 ]
Dany, Abi Gerges [7 ]
Walid, Moukadem [8 ]
Chadi, Saba [9 ]
机构：
[1] Amer Univ Beirut, Med Ctr, Beirut, Lebanon
[2] Hotel Dieu de France, Beirut, Lebanon
[3] Mt Lebanon Hosp, Beirut, Lebanon
[4] St Joseph Hosp, Beirut, Lebanon
[5] Hammoud Hosp Univ, Med Ctr, Saida, Lebanon
[6] St George Hosp Univ, Med Ctr, Beirut, Lebanon
[7] Middle East Inst Hlth, Bsalim, Lebanon
[8] Haykal Hosp Tripoli, Tripoli, Lebanon
[9] Roche, Beirut, Lebanon
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-306
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
    Sehouli, Jalid
    Mustea, Alexander
    Oskay-Ozcelik, Guelten
    Keller, Maren
    Richter, Rolf
    Tome, Oliver
    Woopen, Hannah
    Sommer-Joos, Ann-Katrin
    Grabowski, Jacek P. P.
    Armbrust, Robert
    Wimberger, Pauline
    CANCERS, 2021, 13 (19)
  • [42] AVANTI: A non-interventional study examining the combination of bevacizumab with paclitaxel or capecitabine in metastatic breast cancer
    Schneeweiss, A.
    Fett, W.
    Aktas, B.
    Fruehauf, S.
    Grafe, A.
    Jakob, A.
    Foerster, F.
    Mueller, V.
    CANCER RESEARCH, 2013, 73
  • [43] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [44] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Safont, M. J.
    Salud, A.
    Losa, F.
    Garcia-Giron, C.
    Bosch, C.
    Escudero, P.
    Lopez, R.
    Madronal, C.
    Bolanos, M.
    Gil, M.
    Llombart, A.
    Castro-Carpeno, J.
    Gonzalez-Baron, M.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1468 - 1473
  • [45] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [47] Place of first-line palliative chemotherapy in patients with metastatic colorectal cancer
    Hebbar, M
    REVUE DE MEDECINE INTERNE, 1997, 18 : S364 - S367
  • [48] Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy
    Maddalena, C.
    Ponsiglione, A.
    Camera, L.
    Santarpia, L.
    Pasanisi, F.
    Bruzzese, D.
    Panico, C.
    Fiore, G.
    Camardella, S.
    Caramia, T.
    Farinaro, A.
    De Placido, S.
    Carlomagno, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S178 - S178
  • [49] Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.
    Murai, Katsuyuki
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Hamauchi, Satoshi
    Sugiyama, Keiji
    Tsushima, Takahiro
    Mitani, Seiichiro
    Todaka, Akiko
    Honda, Kazunori
    Yokota, Tomoya
    Narita, Yukiya
    Machida, Nozomu
    Kadowaki, Shigenori
    Fukutomi, Akira
    Ura, Takashi
    Onozawa, Yusuke
    Ando, Masashi
    Yasui, Hirofumi
    Muro, Kei
    Yamazaki, Kentaro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [50] First-line bevacizumab (bev) plus paclitaxel (pac) combination therapy: safety findings (n=165) from a multicentre German non-interventional study in patients with metastatic breast cancer (MBC)
    Foerster, F.
    Geberth, M.
    Schumacher, C.
    Schneeweiss, A.
    Weinberg, R.
    Hahn, L.
    Hertz-Eichenrode, M. M.
    Klare, P.
    Tesch, H.
    Schmidt, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 283 - 283
12345